Provided herein are novel synthetic compounds having the structure of formula (1),

##STR00001##

wherein X is a substituted or unsubstituted aromatic or heteroaromatic mono- or polycyclic ring system; and Y is substituted or unsubstituted C.sup.5-C.sup.10 alkyl or alkenyl group, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium.

Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description

##STR00001##

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001##

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001##

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.

##STR00001##

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.

##STR00001##

Dried and or decarboxylated cannabis containing a known composition of cannabinoids is blended with other dried or decarboxylated cannabis of a known composition of cannabinoids and or mixed with other extracts of, isolates of, cannabisor synthetic cannabinoids to achieve a prescribed amount of cannabinoids in the blend. Decarboxylated cannabis is preferentially produced using controlled thin layer decarboxylation. Precision decarboxylation is optionally used to produce a precise pair ratio of acidic to neutral cannabinoid, eg THCA to THC or CBDA to CBD. Further a prescribed or selected terpene profile is mixed and applied to the blend. Once mixed the plant material is suitable for ingestion without further treatment and is dosed appropriately.

Dried and or decarboxylated cannabis containing a known composition of cannabinoids is blended with other dried or decarboxylated cannabis of a known composition of cannabinoids and or mixed with other extracts of, isolates of, cannabisor synthetic cannabinoids to achieve a prescribed amount of cannabinoids in the blend. Decarboxylated cannabis is preferentially produced using controlled thin layer decarboxylation. Precision decarboxylation is optionally used to produce a precise pair ratio of acidic to neutral cannabinoid, eg THCA to THC or CBDA to CBD. Further a prescribed or selected terpene profile is mixed and applied to the blend. Once mixed the plant material is suitable for ingestion without further treatment and is dosed appropriately.